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We investigated whether culture conditions could affect the RANTES antiviral effect on human immunodeficiency virus type
1 (HIV-1) infection of primary macrophages. Monocyte-derived macrophages (MDM) were obtained either as (1) the adherent
cells of 5-day cultures of blood mononuclear cells (PBMC), followed by 2 days without nonadherent PBMC or added cytokines
(MDM-5d), or (2) as the adherent cells recovered from 1-h incubation of PBMC, which were cultured for 7 days with
macrophage colony-stimulating factor (M-CSF; MDM-MCSF). Infection of MDM-5d from different donors with HIV-1 R5
strains was reproducibly inhibited by RANTES (IC50 # 10 nM), but infection of MDM-MCSF was not inhibited by $100 nM
RANTES, even when added at initiation of cultures, although it was still inhibited by a CD4 antibody. RANTES had no antiviral
effect when MDM-5d were treated with physiological concentrations of M-CSF or GM-CSF before infection. CCR5 and CXCR4
expression as well as that of other cell surface molecules, including adhesion molecules, was not affected by the cytokines.
MDM-MCSF from D32CCR5 homozygous individuals did not render them permissive to HIV-1, suggesting that it is unlikely
that the virus uses another coreceptor. RANTES binding to MDM was chondroitin sulfate, but not heparan sulfate, dependent,
and RANTES bound more efficiently to MDM-5d than to MDM-MCSF. Chondroitin sulfate removal partially offset the RANTES
antiviral effect for MDM-5d. Thus RANTES anti-HIV-1 activity for primary macrophages depends on culture conditions and
their consequent activation status, which may lead to differences in proteoglycan surface expression. These data may be
relevant for the development of chemokine-based therapy for HIV-1 infection. © 1998 Academic Press
INTRODUCTION
The chemokine receptor CCR5 is the major coreceptor of
human immunodeficiency virus type 1 (HIV-1) macrophage-
tropic (Alkhatib et al., 1996; Choe et al., 1996; Deng et al.,
1996; Doranz et al., 1996; Dragic et al., 1996), mostly R5
strains (Berger et al., 1998). CCR5 ligands [RANTES (regu-
lated on activation normal T cell expressed and secreted),
macrophage inflammatory protein (MIP)-1a, MIP-1b, and
their analogs] inhibit infection by R5 strains of cells ex-
pressing both CCR5 and HIV-1 primary receptor CD4, in-
cluding blood T lymphocytes (Alkhatib et al., 1996; Dragic
et al., 1996; Cocchi et al., 1995; Simmons et al., 1997;
Ylisastigui et al., 1998). Paradoxically, experimental evi-
dence as to whether these chemokines affect infection of
CCR5-expressing primary macrophages is still discordant
(Arenzana-Seisdos et al., 1996; Capobianchi et al., 1998;
Dragic et al., 1996; Oravecz et al., 1997; Schmidt-Mayerova
et al., 1996, Simmons et al., 1997; Verani et al., 1997;
Ylisastigui et al., 1998).
Macrophages play an important role in the pathogen-
esis of HIV-1 infection. They are among the first cells to
be infected and possibly as important a virus reservoir
as CD41 T lymphocytes in infected patients (Chun et al.,
1997; Meltzer et al., 1990). Blocking the appropriate
b-chemokine receptors on both cell types is presently
considered as a therapeutical approach against HIV-1
(Arenzana et al., 1996; Simmons et al., 1997; Ylisastigui et
al., 1998), but in contrast to T lymphocytes, it is not clear
whether it is possible to inhibit HIV-1 infection of primary
macrophages in this manner. Thus clarifying this point is
a requisite for developing new drugs based on b-che-
mokine derivatives. The discrepant findings on the effect
of b-chemokines on HIV-1 infection of macrophages may
be due to variations related to culture conditions and/or
cell donors that would influence CCR5 cell surface ex-
pression (Trkola et al., 1996; Wu et al., 1997), a critical
parameter for assessing the antiviral activity of CCR5
ligands. Culture conditions may also influence the mac-
rophage activation status, leading to variable expression
of cell surface-associated or secreted molecules that
affect HIV-1 permissivity, such as cytokines and proteo-
glycans (Fauci, 1996; Oravecz et al., 1997; Wagner et al.,1 To whom reprint requests should be addressed.
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1998). These in vitro conditions may reflect different
physiological states of the macrophages in vivo.
We examined these possibilities by using RANTES as
the most potent b-chemokine inhibitor of HIV-1 infection
[two R5 strains (HIV-1Ba-L, HIV-1Ada) and monocyte-de-
rived macrophages (MDM) from the same healthy do-
nors obtained under two conditions] (1) as the adherent
cells of 5-day culture of blood mononuclear cells (PBMC)
without exogenous growth factor, after which nonadher-
ent cells were removed and adherent cells were cultured
further for 2 days before exposure to HIV-1, as described
(Benjouad et al., 1997; Seddiki et al., 1996) or (2) as
adherent monocytes recovered from 1-h incubation of
PBMC, which were subsequently cultured for 7 days with
macrophage colony-stimulating factor (M-CSF), a macro-
phage differentiation and survival factor (Clark et al.,
1987). We found that RANTES affected differently HIV-1
infection of MDM depending on the culture conditions.
RESULTS
Effect of RANTES on HIV-1 infection of MDM
depends on culture conditions
Although it is demonstrated that b-chemokines RANTES,
MIP-1a, and MIP-1b inhibit infection of T lymphocytes by
R5 strains, there is no consensus as to whether they
affect infection of primary macrophages (Arenzana-
Seisdos et al., 1996; Capobianchi et al., 1998; Dragic et
al., 1996; Moriuchi et al., 1996; Oravecz et al., 1997;
Schmidt-Mayerova et al., 1996; Simmons et al., 1997;
Verani et al., 1997; Ylisastigui et al., 1998). Indeed, there
are different methods to obtain and culture primary mac-
rophages, which use exogenous growth factors or does
not, and such differences may account for the conflicting
reports. Using RANTES as the most potent b-chemokine
inhibitor of HIV-1 infection, we examined whether the
antiviral effect of a b-chemokine on HIV-1 infection of
MDM could be influenced by such conditions.
We verified first that in our hands, RANTES actually
inhibited infection of PHA-activated blood T lymphocytes
by R5 strains HIV-1Ba-L or HIV-1Ada but not by X4 strain
HIV-1lai, whereas SDF-1a inhibited HIV-1lai but not
HIV-1Ba-L infection and that neither MDM preparation
was susceptible to HIV-1lai (Ylisastigui et al., 1998; data
not shown).
We then verified that both MDM preparations were
87–99% CD141, without detectable contaminating T and
B lymphocytes as indicated by a lack of CD3 and CD20
labeling (Fig. 1). MDM were incubated with different
chemokines, exposed to virus, and cultured further with
the initial chemokine. As reported (Ylisastigui et al.,
1998), RANTES inhibited HIV-1Ba-L infection of MDM-5d
(Fig. 2a), but no inhibition was noted with MCP-1 or
SDF-1a used as controls. RANTES concentrations that
completely inhibited HIV-1 production were regularly in
the 20–30 nM range (Fig. 2b), with an IC50 of #10 nM.
Surprisingly, even 100 nM RANTES or higher concentra-
tions (data not shown) did not inhibit HIV-1 infection of
MDM-MCSF from the same donors (Fig. 2c), which nev-
ertheless was inhibited by 0.5 mg/ml Leu3a monoclonal
antibody (mAb) or 5 mM AZT (data not shown) but not by
100 nM SDF-1a or by a mixture of SDF-1a and RANTES.
The same pattern was found with MDM from different
donors infected with either HIV-1Ba-L or HIV-1Ada (data not
shown). These data indicate that culture conditions are
critical to reveal the antiviral activity of a b-chemokine on
HIV-1 infection of primary macrophages.
RANTES antiviral effect may in fact be related to CCR5
downregulation (Alkhatib et al., 1997; Amara et al., 1997),
an effect possibly promoted by prolonged treatment of
cells with RANTES. However, RANTES did not inhibit
HIV-1 infection of MDM-MCSF, even when these were
continuously cultured with 100 nM RANTES starting from
day 0 (i.e., for 7 days before exposure to virus) (Fig. 2c).
When we examined if M-CSF modified the suscepti-
bility of MDM from D32CCR5 homozygous individuals to
FIG. 1. FACS analysis of culture day 7 MDM. Cells were labeled with mAb to CD14, CD3, or CD20 (solid line) or the corresponding isotype controls
(dotted line). Data are representative of three independent experiments using different donors.
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HIV-1Ba-L, we found that these cells could not be infected
in the presence as well as in the absence of M-CSF (data
not shown). Thus it is unlikely that the virus uses a
coreceptor other than CCR5 to infect MDM.
M-CSF antagonizes the effect of RANTES on HIV-1
infection of MDM
We next examined the possibility that lack of RANTES-
inhibiting effect on HIV-1 infection of MDM-MCSF was
due to the presence of M-CSF in the cultures; by adding
M-CSF to MDM-5d on day 7, before infection, RANTES
antiviral effect then was abolished (Fig. 3a). Of note, virus
production was regularly increased in the presence of
M-CSF.
We also tested whether virus produced by MDM-
MCSF was susceptible to RANTES. When MDM-5d were
infected with HIV-1Ba-L supernatant produced by MDM-
MCSF (Fig. 3b), no inhibition was noted with RANTES.
These observations indicate that the effect of RANTES
on MDM infection with the same HIV-1 strain may differ
depending on the MDM culture conditions and accord-
ing to how the HIV-1-infecting supernatant is produced.
Thus M-CSF may directly or indirectly antagonize the
effect of RANTES.
To examine whether such an effect was specific for
M-CSF or could be induced by another cytokine, we used
GM-CSF to prepare MDM. Again, we found that treat-
ment of MDM-5d with GM-CSF abolished RANTES anti-
HIV-1 activity (data not shown).
Effect of culture conditions on the expression of
MDM surface molecules
We then investigated the expression of CD4 and of
chemokine receptors, which could affect MDM suscep-
tibility to HIV-1, under the two culture conditions. FACS
analysis showed limited but reproducible increase of
CD4 expression on day 7 MDM-MCSF relative to their
MDM-5d counterparts from the same donors; CCR5 and
CXCR4 expression was not affected, and no CCR3 ex-
pression was detected under either condition (Fig. 4 and
Table 1). Similar results were obtained when MDM-5d
was treated with GM-CSF from days 5–7, except that CD4
FIG. 2. Effect of RANTES on the infection of MDM by HIV-1Ba-L. (a) Infection of MDM-5d. C1 indicates control infection without added chemokine;
RANTES 1, cells were pretreated for 30 min before infection and further cultured with 100 nM RANTES; MCP-1 (100 nM) and SDF-1a (100 nM) were
used in the same manner as RANTES 1. (b) Dose-dependent inhibition by RANTES of MDM-5d infection. (c) Infection of MDM-MCSF. RANTES 2
indicates cells were cultured with 100 nM RANTES for 7 days before and continuously after infection; Leu-3a, cells were treated with 0.5 mg/ml
anti-Leu3a mAb in the same manner as with RANTES 1. Data are representative of six experiments using different donors.
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expression then was not modified (data not shown). Thus
modifications of CD4 or of CCR5 expression cannot ac-
count for the lack of RANTES anti-HIV-1 activity for MDM-
MCSF.
MDM express other surface molecules that can attach
to the virus and may promote fusion of the virus and cell
membranes (Arthur et al., 1992; Frank et al., 1996; LeNa-
our et al., 1997; Saarloos et al., 1997; Seddiki et al., 1996).
Therefore, we investigated expression of the after adhe-
sion molecules and members of the Ig and b2-integrin
subfamilies but found no differences under either culture
condition (Table 1): CD11a (LFA-1: integrin aL), CD54
(ICAM-1), CD18 (integrin b2), CD80 (B7–1), HLA-DR,
CD11b (Mac-1, integrin am subunits), CD64 (FcgR1),
CD14 (LPS receptor), CD11c (integrin ax), and CD58
(LFA-3).
Role of proteoglycans in RANTES binding to MDM
and antiviral activity
The expression of proteoglycans depends on cell dif-
ferenciation and activation (Uhlin-Hansen et al., 1989,
Wagner et al., 1998; Yeaman and Rapraeger, 1993). Sur-
face sulfated proteoglycans have been shown to affect
RANTES binding to at least PM-1 cells and enable in this
manner its anti-HIV-1 activity (Oravecz et al., 1997; Wag-
ner et al., 1998). Here, we examined whether the different
sensitivity to RANTES anti-HIV-1 activity of MDM pre-
FIG. 3. M-CSF affects RANTES capacity to inhibit HIV-1Ba-L infection of MDM. (a) MDM-5d were treated with 50 U/ml M-CSF (*), or not before
infection in the absence (C1 vs C1*) or the presence of RANTES 1 (same as in Fig. 2). (b) MDM-5d were infected with supernatant from
HIV-1Ba-L-infected MDM-MCSF (§) or MDM-5d in the absence (C1 vs C1§) or the presence of RANTES 1. Data are representative of three experiments
using different donors.
FIG. 4. Culture day 7 MDM membrane expression of CD4 and chemokine receptors. MDM-5d and MDM-MCSF from the same donors were labeled
with CD4, CCR5, CCR3, and CXCR4 mAb (solid line) or with isotype control antibodies (dotted line). Data are representative of four experiments using
different donors.
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pared under either of our two conditions may be ac-
counted for by differences in RANTES binding.
Indeed, RANTES bound in a dose-dependent manner
to MDM-5d, more efficiently than to MDM-MCSF (Fig.
5a); for example, it bound only weakly to MDM-MCSF at
100 nM, a concentration that did not protect the cells
from HIV. Treatment with MDM-5d with chondroitinase,
which removes surface chondroitin sulfate, inhibited
RANTES binding, but no effect was noted with hepariti-
nase-treated cells; the effect of chondroitinase on the
much weaker RANTES binding to MDM-MCSF was less
obvious than that for MDM-5d (Fig. 5b). These data
suggest that the lack of RANTES antiviral activity for
MDM-MCSF is related to its decreased ability to bind to
MDM, presumably because they express no or low chon-
droitin sulafte.
To ascertain the role of chondroitin sulfate in RANTES
antiviral activity, chondroitinase-treated MDM-5d were
infected in the presence of RANTES. Chondroitinase
treatment partially offset the inhibitory effect of RANTES
on HIV infection of MDM-5d relative to control or hep-
aritinase-treated MDM-5d (Fig. 5c), which strongly sug-
gests that RANTES antiviral effect for MDM could be
mediated by its interaction with chondroitin sulfate.
DISCUSSION
Among HIV-1 target cells (Levy, 1993), CD41 T lympho-
cytes are susceptible to both X4 and R5 strains, whereas
macrophages are susceptible only to R5 strains even
though they also express CXCR4 (current data; Di Marzio
et al., 1998; Naif et al., 1998; Ylisastigui et al., 1998), the
X4 strain coreceptor (Bleul et al., 1996; Feng et al., 1996).
Because both cell types express CCR5, it is assumed
that CCR5 ligands should inhibit infection by R5 strains.
Actually, this has been readily demonstrated for blood T
lymphocytes (Arenzana-Seisdos et al., 1996; Cocchi et
al., 1995; Simmons et al., 1997; Ylisastigui et al., 1998) but
not always for primary macrophages, although we and
others have shown that b-chemokines or their analogs
inhibit MDM infection by R5 strains (Capobianchi et al.,
1998; Dragic et al., 1996; Moriuchi et al., 1996; Oravecz et
al., 1997; Schmidt-Mayerova et al., 1996; Simmons et al.,
1997; Verani et al., 1997; Ylisastigui et al., 1998).
We hypothesized that the discrepant reports on the
inhibition of HIV-1 infection of MDM by b-chemokines
may be related in part to different culture conditions. This
was confirmed by using two methods to obtain and
culture MDM and the finding that RANTES inhibited in-
fection of MDM-5d but not of MDM-MSCF. Indeed, when
allowed by the description of experimental conditions,
analysis of the literature shows that HIV-1 infection of
MDM is affected by b-chemokines when they are pre-
pared without exogenous growth factors but not when
cultured with factors such as M-CSF or GM-CSF, in
which case infection can even be enhanced (Schmidt-
Mayerova et al., 1996). Thus data of the literature may be
interpreted in the context of the current study.
A major difference between our two protocols is the
use of M-CSF, which induces MDM differentiation and
activation (Meltzer et al., 1990; Young et al., 1990) and
then may directly or indirectly antagonize the RANTES
antiviral effect. Indeed, when MDM-5d were treated with
M-CSF or GM-CSF, a cytokine that also induces macro-
phage activation (Young et al., 1990), and then infected
with HIV-1 or when they were infected with HIV-1-in-
fected supernatant from MDM-MCSF, no inhibition of
infection by even high RANTES concentrations was
noted. Thus RANTES differently affects infection by the
same virus strain according to how the virus is produced.
However, we could not alleviate the effect of M-CSF with
anti-M-CSF antibodies (data not shown), which may be
explained by the fact that MDM may take up MCSF–anti-
M-CSF antibody complexes via their Fc receptors.
M-CSF has been shown to increase HIV-1 production
by MDM (Gruber et al., 1995; Kalter et al., 1991), which we
noted here, likely by increasing CD4 surface expression
(Bergamini et al., 1994). However, we found even if it
might increase HIV-1 binding to MDM, the limited
change of CD4 expression cannot account for RANTES
lack of effect on HIV-1 infection, which should occur
through interference with CCR5, all the more so because
the same low Leu3a mAb concentration inhibited infec-
tion of both MDM-5d and MDM-MCSF to the same de-
gree. In addition, the limited increase of HIV-1 infection in
the presence of M-CSF could not account for the lack of
antiviral effect of $10-fold higher RANTES concentra-
TABLE 1


















Note. MDM obtained under either culture condition were labeled
with mAb to the indicated molecules or with isotype control antibodies.
Expression levels were determined as high (11), intermediate (1), or
undetectable (2) (see Fig. 4 as a reference with respect to CD4, CCR5,
CCR3, and CXCR4 expression).
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tions with these MDM as target cells. This is reinforced
by the fact that GM-CSF, the effect of which on HIV-1
infection of MDM may be opposite to that M-CSF (Ma-
studa et al., 1995), also counteracted the RANTES anti-
viral effect without affecting CD4 expression (data not
shown). Another possibility is that M-CSF or GM-CSF
would increase CCR5 surface expression and thus ren-
der cells more permissive to HIV-1 and less susceptible
to RANTES antiviral effect, but CCR5 expression on
MDM-MCSF or on GM-CSF- or M-CSF-treated MDM-5d
was not modified. However, one might consider that
CCR5 is differently processed or presented on M-CSF-
treated and nontreated cells, which may affect the effi-
cacy of RANTES antiviral effect. It is unlikely that under
such conditions, HIV-1 uses a coreceptor other than
CCR5, as suggested (Cheng-Meyer et al., 1997), because
FIG. 5. Role of proteoglycans in RANTES binding to MDM and antiviral activity. (a) MDM-5d (top) and MDM-MCSF (bottom) were incubated with
10, 30, 100, or 300 nM RANTES and then with a biotinylated goat polyclonal antibody to RANTES or an irrelevant control antibody (C), after which they
were stained with streptavidin-PE. (b) In the same experiment, 300 nM RANTES (300) was incubated with MDM treated with heparitinase (Hep.) or
chondroitinase (Chond.; dotted line), or nontreated MDM, and then processed as above. Open histograms indicate staining by the relevant antibody;
shaded histograms, control labeling with an irrelevant antibody; data are representative of three experiments using different donors. (c) Effect of
proteoglycan removal on RANTES antiviral activity: MDM-5d were treated or not with chondroitinase or heparitinase before being exposed to HIV-1Ba-L
in the presence of 25 nM RANTES [RANTES] or not [control]. The percentage of p24 in the supernatant relative to the control condition [3%] is
indicated. Data are representative of two experiments using different donors.
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MDM from D32CCR5 homozygous individuals are not
susceptible to HIV-1 R5 strains (Rana et al., 1997, Sam-
son et al., 1997), and MDM-MCSF and MDM-5d from
such individuals are both resistant to HIV-1Ba-L infection
(data not shown). Of note, HIV-1Ba-L infection of MDM-
MCSF was not affected by SDF-1a, which confirms that
the virus does not use then CXCR4. Beside CD4 and
chemokines receptors, MDM express adhesion mole-
cules that can attach the virus and assist the fusion
process (Arthur et al., 1992; Frank et al., 1996; LeNaour et
al., 1997; Saarloos et al., 1997), but MDM surface expres-
sion of CD11a, CD54, CD18, CD80, HLA-DR, CD11b,
CD64, CD14, CD11c, and CD58 was not affected under
either of our experimental conditions.
It has been reported that RANTES associates to cell
surface or secreted proteoglycans synthesized by mac-
rophages, and this could be relevant to its antiviral ac-
tivity (Oravecz et al., 1997; Wagner et al., 1998). Lack of
RANTES antiviral activity for macrophages under certain
conditions may thus be ascribed in part to variable ex-
pression of proteoglycans, the metabolism of which is
highly regulated and depends on cell differentiation (Uh-
lin-Hansen et al., 1989, Yeaman and Rapraeger, 1993).
Here, we found that RANTES bound more efficiently to
MDM-5d than to MDM-MCSF, which may explain why
high RANTES concentrations did not affect HIV-1 infec-
tion of MDM-MCSF, whereas lower concentrations inhib-
ited infection of MDM-5d. Most of RANTES binding to
MDM-5d was influenced by chondroitinase but not by
heparitinase, which indicates that RANTES binding to
MDM-5d is chondroitin sulfate dependent as reported by
Oravecz et al. (1997), although their data support the role
of heparan sulfate rather than of chondroitin sulfate in
RANTES antiviral activity for macrophages. Thus MDM
prepared under each condition differently express sur-
face proteoglycans, which may explain in part their dif-
ferent susceptibility to RANTES antiviral effect. Interac-
tion with cell surface chondroitin sulfate may indeed be
important for RANTES antiviral activity, insofar as we
found that chondroitinase treatment partially offset the
inhibitory effect of RANTES on HIV-1Ba-L infection of
MDM-5d, but one may not rule out that differences at the
level of secreted proteoglycans may also affect such
activity (Wagner et al., 1998). The lack of antiviral activity
of RANTES for macrophages reported here and by others
was mainly observed when MDM were cultured with
M-CSF or GM-CSF, which may regulate levels of other
cytokines, particularly those that can downregulate or
enhance HIV-1 replication (Fauci 1996; Kinter et al., 1996;
Poli et al., 1995). Interactions between cytokines and
chemokines are complex, as one cytokine may induce
the activity of a second or block that of a third, especially
with respect to macrophages that are both sources and
targets of these factors (Canque et al., 1996; Meltzer et
al., 1990; Schmidt-Mayerova et al., 1996). Whether cyto-
kines with oppositing effects on HIV-1 replication affect
the metabolism of proteoglycans is presently under in-
vestigation. Nevertheless, our data may also pertain to
the disparate reports as to the possibility of inhibiting
HIV-1 infection of primary macrophages by other anti-HIV
agents such as CD4 mAb, dextran sulfate, or soluble
CD4, both in vitro (Benjouad et al., 1997; Bergamini et al.,
1994; Gendelman et al., 1998; Gomatos et al., 1990; Mit-
suya et al. 1988; Perno et al., 1990; Richman et al., 1987)
and in vivo with respect to at least soluble CD4 deriva-
tives and dextran sulfate (Abrams 1989; Kahn et al.,
1990).
At any rate, our data suggest that under certain con-
ditions, HIV-1 infection of MDM is not susceptible to
RANTES antiviral effect, even when CCR5 is present at
the membrane. This may be explained in part by ineffi-
cient RANTES interactions with cells, likely as a conse-
quence of lack of expression of the appropriate proteo-
glycans. It is possible that what is noted in vitro may also
occur in vivo, insofar as the M-CSF concentrations used
here may be attainable in vivo (Bergamini et al., 1994;
Furasawa et al., 1978). Beyond the fact that our results
reconcile apparently conflicting findings (Arenzana-Seis-
dos et al., 1996; Capobianchi et al. 1998; Dragic et al.,
1996; Schmidt-Mayerova et al., 1996; Oravecz et al., 1997;
Simmons et al., 1997; Verani et al., 1997), they suggest
that the effect of b-chemokines on HIV-1 infection of
primary macrophages should be analyzed and inter-
preted in relation to the macrophage activation state
before attempting to implement chemokine derivative-
based therapy of HIV-1 infection.
MATERIALS AND METHODS
Reagents
Recombinant human chemokines and cytokines
RANTES, stromal cell-derived factor (SDF)-1a, monocyte
chemoattractant protein (MCP)-1, M-CSF, and granulo-
cyte/macrophage colony-stimulating factor (GM-CSF)
were from R&D Systems (Minneapolis, MN). The poly-
colonal anti-M-CSF antibody was from R&D Systems.
Interleukin (IL)-2 was from Boehringer-Mannheim (Mann-
heim, Germany). CD4 [phycoerythrin (PE)-Leu3a], CD14
(FITC-LeuM3), CD54 (PE-Leu54), FITC-anti-HLA-DR,
FITC-CD3, and FITC-CD20 mAbs were from Becton-Dick-
inson (Mountain View, CA); PE-CD11a, PE-CD11b, PE-
CD11c, FITC-CD18, PE-CD58, FITC-CD80 and FITC-CD64
mAb were from Immunotech (Marseille, France); and
anti-CCR5, anti-CCR3, and anti-CXCR4 mAbs were from
the NIH AIDS Reagent Program (Bethesda, MD) or from
R&D Systems.
Cells
Buffy-coat PBMC from healthy donors were isolated by
Ficoll-Paque (Pharmacia, Uppsala, Sweden) centrifuga-
tion, and MDM were obtained according to two proce-
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dures. (1) PBMC were cultured for 5 days in RPMI 1640,
penicillin-streptomycin-neomycin (50 mg/ml), 2 mM glu-
tamine (all from GIBCO BRL, Paisley, UK), 20% FCS
(Boehringer), and 10% heat-inactivated normal human AB
serum (Pitie´-Salpeˆtrie`re Blood Bank), without added ex-
ogenous growth factor, after which nonadherent cells
were removed and adherent cells were further cultured
for 2 days. Nonadherent cells then were removed by
several washes in Ca21- and Mg21-free PBS, and MDM
were cultured in medium with only 20% FCS for another
2 days before use; MDM prepared according to this
procedure are referred to as MDM-5d. (2) Alternatively,
monocytes from the same donors were separated by 1-h
adherence and cultured for 7 days in the same culture
medium, but with only 20% FCS and with 50 U/ml M-CSF
(MDM-MCSF). In some experiments, MDM-5d were cul-
tured from day 5 with 50 U/ml M-CSF or 800 U/ml gran-
ulocyte/macrophage (GM)-CSF.
Immunofluorescence assay
MDM of 7-day cultures were recovered by adding cold
PBS and 0.02% EDTA for 10 min and scrapping off with a
rubber policeman. Cells (5 3 105 in 100 ml PBS, 2% FCS,
0.05% sodium azide) were incubated for 30 min at 4°C
with the relevant mAb or with FITC- or PE-labeled isotype
control mAb. Also, cells were incubated with anti-CCR5,
-CXCR4, or -CCR3 mAbs, washed, and then incubated
with PE-anti-mouse IgG (Fab). After washing, cells were
fixed with 1% paraformaldehyde and analyzed with a
FACScan (Becton Dickinson).
FACS analysis of RANTES binding to MDM
MDM (5 3 105/well) prepared under either condition
were treated or not treated for 1 h at 37°C with 4 mU
heparitinase (EC.4.2.2.8) or chondroitinase (EC.4.2.2.4)
(Sigma, St. Louis, MO) in 200 ml of PBS and 1 mg/ml
bovine serum albumin (PBS–BSA). Cells were washed
and incubated with different concentrations of RANTES
in 200 ml PBS–BSA at 4°C. After 1 h, cells were washed
and incubated for 30 min with a biotinylated goat poly-
clonal antibody to RANTES (1 mg/ml; R&D Systems) or an
irrelevant antibody as control, after which cells were
washed, stained with streptavidin-PE (1:800; Becton-
Dickinson), and examined by FACS analysis.
HIV-1 infection
HIV-1Ba-L (Gartner et al., 1986), a gift from Birgitta A¨sjo
(Bergen, Norway), and HIV-1Ada (Gendelman et al., 1988),
provided by the NIH AIDS Reagent Program, are labora-
tory R5 strains. Laboratory X4 strain HIV-1lai was pur-
chased from Diagnostics Pasteur (Marne-la-Coquette,
France).
Infection of MDM was performed as described (Benj-
ouad et al., 1997; Seddiki et al., 1996): 5 3 105 MDM were
pretreated or not for 30 min with RANTES, SDF-1a,
MCP-1, or the Leu3a mAb and exposed for 18 h to
HIV-1Ba-L (14 ng/ml p24) or HIV-1Ada (7 ng/ml p24) in 1 ml
of culture medium. Excess virus was washed away, and
cells were cultured further with the same chemokines or
mAbs at the same concentration. In some experiments,
MDM were pretreated with RANTES from culture day 0 or
day 5 onward before infection. Alternatively, MDM-5d
were treated with chondroitinase or heparitinase, as
above, before being exposed to HIV-1Ba-L in the presence
of various concentrations of RANTES, and the enzyme
was added thereafter at 1 mU/ml twice a week to culture
medium.
Lymphocytes (5 3 105), obtained by stimulation of
normal PBMC with PHA (DIFCO, Detroit, MI) for 3 days,
were pretreated for 30 min with the same preparations
as above and mixed thereafter with virus for 2 h in
IL-2-supplemented culture medium, as reported previ-
ously (Benjouad et al., 1997). Cells were then washed
and cultured at 5 3 105/ml in IL-2-supplemented culture
medium with the chemokines or mAbs at initial concen-
trations (Ylisastigui et al., 1998).
Virus production by HIV-1-infected MDM and PHA-
activated T lymphocyte cultures was assessed by mea-
suring p24 in cell-free supernatants collected twice a
week, as reported previously (Benjouad et al., 1997; Yli-
sastigui et al., 1998).
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